Metformin Reduces Cardiometabolic Risk Factors in People at High Risk for Development of Type 2 Diabetes and Cardiovascular DiseasePetya Kamenova1*, Iliyana Atanasova2 and Georgi Kirilov3
- *Corresponding Author:
- Petya Kamenova
Department of Diabetology
Clinical Center of Endocrinology and Gerontology
Medical University, No 2, Zdrave str., 1431, Sofia, Bulgaria
E-mail: [email protected]
Received date: October 22, 2014; Accepted date: November 16, 2014; Published date: November 18, 2014
Citation: Kamenova P, Atanasova I, Kirilov G (2014) Metformin Reduces Cardiometabolic Risk Factors in People at High Risk for Development of Type 2 Diabetes and Cardiovascular Disease. J Diabetes Metab 5:470. doi:10.4172/2155-6156.1000470
Copyright: © 2014 Kamenova P, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Background: The aim of the study was to investigate the effect of metformin on cardiometabolic risk factors as visceral obesity, hyperinsulinaemia, insulin resistance, dyslipidaemia and arterial hypertension in hyperinsulinaemic normal glucose tolerant people with metabolic syndrome who represent a high-risk group for development of type 2 diabetes and cardiovascular disease.
Methods: 52 participants (20 men/32 women) of mean age 40.1 ± 14.2 yrs were included in an open-label prospective one year observational clinical study in which cardiometabolic risk markers at three months intervals were followed. Metformin was applied at a mean dose of 2.55 ± 0.2 g daily on a usual diet and physical activity.
Results: Body mass index, waist circumference, fasting serum insulin and homeostasis model assessment of insulin resistance significantly reduced at 6, 9 month and at 1 year of metformin treatment (all p<0.001). Fasting plasma glucose and 2-h post glucose load serum insulin significantly decreased at 3, 6, 9 month and at 1 year (both p<0.001). Triglycerides, systolic and distolic blood pressure significantly decreased at 9 month and at 1 year (all p<0.001). LDL cholesterol significantly reduced at 9 month and at 1 year (p=0.001). HDL cholesterol significantly increased at 1 year of metformin treatment (p<0.001).
Conclusion: Metformin reduces cardiometabolic risk factors in hyperinsulinaemic, normal glucose tolerant people with metabolic syndrome and could be considered as a therapeutic option for prevention of type 2 diabetes and cardiovascular disease.